133 related articles for article (PubMed ID: 30502046)
1. Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.
Cholley T; Thiery-Vuillemin A; Limat S; Hugues M; Calcagno F; Mouillet G; Anota A; Nerich V
Clin Genitourin Cancer; 2019 Feb; 17(1):e227-e234. PubMed ID: 30502046
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
4. In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013.
Maroun R; Maunoury F; Benjamin L; Nachbaur G; Durand-Zaleski I
PLoS One; 2016; 11(9):e0162864. PubMed ID: 27649305
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
6. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
7. The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis.
Antczak C; Trinh VQ; Sood A; Ravi P; Roghmann F; Trudeau V; Chang SL; Karakiewicz PI; Kibel AS; Krishna N; Nguyen PL; Saad F; Sammon JD; Sukumar S; Zorn KC; Sun M; Trinh QD
J Urol; 2014 Jun; 191(6):1678-84. PubMed ID: 24384157
[TBL] [Abstract][Full Text] [Related]
8. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
Chien CR; Geynisman DM; Kim B; Xu Y; Shih YT
Pharmacoeconomics; 2019 Mar; 37(3):301-331. PubMed ID: 30467701
[TBL] [Abstract][Full Text] [Related]
10. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
11. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
12. Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.
Thiery-Vuillemin A; Cholley T; Calcagno F; Hugues M; Maurina T; Limat S; Nguyen Tan Hon T; Almotlak H; Mouillet G; Nerich V
Clin Genitourin Cancer; 2018 Apr; 16(2):e297-e305. PubMed ID: 29066073
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
14. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
15. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
16. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).
Tsironis G; Koutsoukos K; Athanasakis K; Tsiara A; Tzannis K; Gerolympou M; Visvikis A; Oikonomopoulos G; Kollia A; Giannopoulou E; Dimitra M; Kostouros E; Papatsoris A; Dellis A; Stravodimos K; Varkarakis I; Samantas E; Aravantinos G; Kentepozidis N; Christodoulou C; Bozionelou V; Dimopoulos MA; Bamias A
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):491-501. PubMed ID: 30417707
[No Abstract] [Full Text] [Related]
17. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
18. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Ondrácková B; Demlová R; Komínek J
Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
[TBL] [Abstract][Full Text] [Related]
19. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
